Business
TriSalus Reports Q4 and Full Year 2023 Financial Results and Business Update
Reported revenues of $5.7 million in 4Q23, up 77% over prior year Full year revenues of $18.5 million, up 49% over prior year Gross Margin of 90% in 4Q23 and
About this update from Trisalus Life Sciences, Inc.
[{"type":"text","content":"\n\nReported revenues of $5.7 million in 4Q23, up 77% over prior year\n\n\n\nFull year revenues of $18.5 million, up 49% over prior year\n\n\n\nGross Margin of 90% in 4Q23 and 86% for full year\n\n\n\nCMS reimbursement granted for the TriNav® Infusion System via assignment of an HCPCS code\n\n\n\nReal-world data published on TriNav system demonstrating significant improvement in the delivery of therapeutics to liver tumors for patients with higher disease burden\n\n\n\nReceived 510k clearance of TriNav Large and TriGuide systems\n\n\n\nCompleted enrollment in phase 1 clinical trials (100 patients) in several liver indications; data will be analyzed in the second half of 2024\n\n\n\nInitiated first-in-man clinical trial of its novel pancreatic infusion technology (510k cleared), plus nelitolimod, to demonstrate safety and efficacy\n\n\n\n DENVER & SALT LAKE CITY--(BUSINESS WIRE)--\nTriSalus Life Sciences Inc., (Nasdaq: TLSI), today announced its financial results for the fourth quarter and full year ended December 31, 2023, and provided a business update.\n\n\n“2023 was a critical year for TriSalus, underscored by significant growth in TriNav revenue, a landmark achievement of permanent reimbursement, and disciplined progress within our technology and clinical pipelines,” said Mary Szela, Chief Executive Officer and President of TriSalus.\n\n\n“The release of compelling real-world evidence demonstrating the impactful benefits of the TriNav method for complex patients, along with the exploration of nelitolimod in conjunction with the TriNav system through selected phase 1 clinical studies, reinforces our commitment to improving care options for oncology patients. As an example, the phase 1 clinical trial for locally advanced pancreatic patients utilizes our novel pancreatic infusion device in combination with nelitolimod with a goal to demonstrate improved outcomes for pancreatic patients.\n\n\nFurthermore, receiving 510k clearance of a larger vessel size of the TriNav system, and successfully accessing the public markets underscore our dedication to advancing our company for sustained growth and success. As we reflect on the achievement of the past year, we recognize not only the milestones achieved but also acknowledge the solid foundation for continued future progress across the business, and we remain fully focused and committ...